Several antiretroviral drugs can be or have the potential to be used once daily.
Studies are also underway to investigate the feasibility of once-daily protease inhibitor therapy.
The patients had very good virologic and immunologic responses to therapy. Median viral load reduction was greater than 3.4 log and CD4 counts rose from 250 to 449 at 48 weeks. The significant dropout rate somewhat limits the interpretation of the study results. Three other patients were withdrawn from the study because of non-adherence to therapy. EFV is the best once daily regimen.